CL2023003068A1 - Compuestos, composiciones y métodos para el tratamiento de trastornos - Google Patents

Compuestos, composiciones y métodos para el tratamiento de trastornos

Info

Publication number
CL2023003068A1
CL2023003068A1 CL2023003068A CL2023003068A CL2023003068A1 CL 2023003068 A1 CL2023003068 A1 CL 2023003068A1 CL 2023003068 A CL2023003068 A CL 2023003068A CL 2023003068 A CL2023003068 A CL 2023003068A CL 2023003068 A1 CL2023003068 A1 CL 2023003068A1
Authority
CL
Chile
Prior art keywords
compounds
methods
compositions
treating cancer
cancer
Prior art date
Application number
CL2023003068A
Other languages
English (en)
Inventor
Bi Yingzhi
Carson Ken
Cirillo Harriman Geraldine
A B Hone Graham
Gandhi Govindaraj Rajiv
Aldrin Denny Rajiah
J Diller David
Original Assignee
Hotspot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hotspot Therapeutics Inc filed Critical Hotspot Therapeutics Inc
Publication of CL2023003068A1 publication Critical patent/CL2023003068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación incluye, entre otras cosas, compuestos que tratan o disminuyen la gravedad del cáncer, composiciones farmacéuticas y métodos de fabricación y uso de estas.
CL2023003068A 2021-04-16 2023-10-13 Compuestos, composiciones y métodos para el tratamiento de trastornos CL2023003068A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US202163281493P 2021-11-19 2021-11-19

Publications (1)

Publication Number Publication Date
CL2023003068A1 true CL2023003068A1 (es) 2024-05-03

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003068A CL2023003068A1 (es) 2021-04-16 2023-10-13 Compuestos, composiciones y métodos para el tratamiento de trastornos

Country Status (14)

Country Link
US (1) US20240228482A1 (es)
EP (1) EP4323358A1 (es)
JP (1) JP2024514339A (es)
KR (1) KR20240037184A (es)
AU (1) AU2022256514A1 (es)
BR (1) BR112023021068A2 (es)
CA (1) CA3215395A1 (es)
CL (1) CL2023003068A1 (es)
CO (1) CO2023015484A2 (es)
IL (1) IL307732A (es)
MX (1) MX2023012245A (es)
PE (1) PE20240767A1 (es)
TW (1) TW202309023A (es)
WO (1) WO2022221704A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
US20250042896A1 (en) * 2021-10-29 2025-02-06 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Polycyclic compound as cbl-b inhibitor
AU2022379959A1 (en) 2021-11-05 2024-05-09 Genentech, Inc. Lactams as cbl-b inhibitors selective over c-cbl
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
EP4554570A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
AU2023307165A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
CA3261875A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4558504A1 (en) * 2022-07-18 2025-05-28 Insilico Medicine IP Limited Cbl-b inhibitors and methods of uses thereof
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
EP4653436A1 (en) * 2023-01-19 2025-11-26 Guangzhou Yufan Nantu Biotechnologies Co., Ltd Heterocyclic compounds, preparation method therefor and use thereof
CN120530105A (zh) * 2023-01-20 2025-08-22 海南先声再明医药股份有限公司 取代的三环化合物及其应用
WO2024227436A1 (en) * 2023-05-04 2024-11-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025067342A1 (zh) * 2023-09-27 2025-04-03 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
MY150032A (en) * 2007-07-19 2013-11-29 Merck Sharp & Dohme Heterocyclic amide compounds as protein kinase inhibitors
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
CA3041650A1 (en) * 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
WO2019131575A1 (ja) * 2017-12-26 2019-07-04 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
CA3136348A1 (en) * 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
MX2021015675A (es) * 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法
EP4554570A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
AU2023307165A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
CA3261875A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation

Also Published As

Publication number Publication date
AU2022256514A1 (en) 2023-10-19
MX2023012245A (es) 2024-03-11
KR20240037184A (ko) 2024-03-21
WO2022221704A1 (en) 2022-10-20
CO2023015484A2 (es) 2023-11-30
JP2024514339A (ja) 2024-04-01
TW202309023A (zh) 2023-03-01
EP4323358A1 (en) 2024-02-21
BR112023021068A2 (pt) 2024-01-23
PE20240767A1 (es) 2024-04-17
US20240228482A1 (en) 2024-07-11
IL307732A (en) 2023-12-01
CA3215395A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CL2022000922A1 (es) Aminas bicíclicas como inhibidores de la cdk2.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
UY38476A (es) Inhibidores de arg1 y/o arg2
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
MX2020010469A (es) Inhibidores del atf6 y sus usos.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
ECSP20082339A (es) Moduladores de la expresión de apol1
CO2022000481A2 (es) Inhibidores de enzimas
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
MX2020009147A (es) Moduladores de la expresion de irf4.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
CL2024002371A1 (es) Compuestos con estructura en t formada por al menos cuatro ciclos para tratamiento del cáncer
PE20201349A1 (es) Moduladores de la expresion de ezh2
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CO2025016192A2 (es) Moléculas y métodos de uso de estas
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
UY38472A (es) Moduladores de la expresión de foxp3
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
MX2024005379A (es) Agonista de tlr7 y combinaciones para el tratamiento del cancer.
AR117079A1 (es) Moduladores de la expresión de foxp3
BR112022008365A2 (pt) Inibidores de cd73